In vivo evidence for long-term CNS toxicity, associated with chronic binge use of methamphetamine

Drug and Alcohol Dependence

Volumn 111, Issue 1-2, 2010, Pages 155-160

  Chung, Yong An ^a   Peterson, Bradley S ^b   Yoon, Sujung J ^a   Cho, Sung Nam ^c   Chai, Sukhi ^d   Jeong, Jaeseung ^b,e   Kim, Dai Jin ^a  

^a The Catholic University of Korea   (South Korea)

^b New York State Psychiatric Institute ^*  (United States)

^c Bugok National Hospital   (South Korea)

^d Eulji University   (South Korea)

^e Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Cerebral blood flow; Methamphetamine; SPECT; SPM; Toxicity

Indexed keywords

METHAMPHETAMINE;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN BLOOD FLOW; BRAIN REGION; BRAIN TOXICITY; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DRUG DEPENDENCE; HUMAN; IN VIVO STUDY; MALE; MONOAMINERGIC NERVE; NEUROTRANSMISSION; PERFUSION; PONS; PREFRONTAL CORTEX; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS;

ADULT; AMPHETAMINE-RELATED DISORDERS; BRAIN; BRAIN MAPPING; CEREBROVASCULAR CIRCULATION; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHAMPHETAMINE; MIDDLE AGED;

EID: 77956189166     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.04.005     Document Type: Article

References (52)

1. Aguirre G.K., Zarahn E., D'Esposito M. The inferential impact of global signal covariates in functional neuroimaging analyses. Neuroimage 1998, 8:302-306.
2. Alhassoon O.M., Dupont R.M., Schweinsburg B.C., Taylor M.J., Patterson T.L., Grant I. Regional cerebral blood flow in cocaine- versus methamphetamine-dependent patients with a history of alcoholism. Int. J. Neuropsychopharmacol. 2001, 4:105-112.
3. Antonini A., Kazumata K., Feigin A., Mandel F., Dhawan V., Margouleff C., Eidelberg D. Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET. Mov. Disord. 1998, 13:268-274.
4. Barr A.M., Panenka W.J., MacEwan G.W., Thornton A.E., Lang D.J., Honer W.G., Lecomte T. The need for speed: an update on methamphetamine addiction. J. Psychiatry Neurosci. 2006, 31:301-313.
5. Brooks D.J. The early diagnosis of Parkinson's disease. Ann. Neurol. 1998, 44:S10-18.
6. Burrows K.B., Meshul C.K. High-dose methamphetamine treatment alters presynaptic GABA and glutamate immunoreactivity. Neuroscience 1999, 90:833-850.
7. Chang L., Ernst T., Speck O., Patel H., DeSilva M., Leonido-Yee M., Miller E.N. Perfusion MRI and computerized cognitive test abnormalities in abstinent methamphetamine users. Psychiatry Res. 2002, 114:65-79.
8. Chang L., Alicata D., Ernst T., Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 2007, 102(Suppl. 1):16-32.
9. Chung H., Park M., Hahn E., Choi H., Choi H., Lim M. Recent trends of drug abuse and drug-associated deaths in Korea. Ann. N.Y. Acad. Sci. 2004, 1025:458-464.
10. Cohen J.B., Dickow A., Horner K., Zweben J.E., Balabis J., Vandersloot D., Reiber C. Abuse and violence history of men and women in treatment for methamphetamine dependence. Am. J. Addict./Am. Acad. Psychiatr. Alcohol. Addict. 2003, 12:377-385.
11. Cubells J.F., Rayport S., Rajendran G., Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 1994, 14:2260-2271.
12. D'Astous M., Mickley K.R., Dluzen D.E., Di Paolo T. Differential protective properties of estradiol and tamoxifen against methamphetamine-induced nigrostriatal dopaminergic toxicity in mice. Neuroendocrinology 2005, 82:111-120.
13. Desjardins A.E., Kiehl K.A., Liddle P.F. Removal of confounding effects of global signal in functional MRI analyses. Neuroimage 2001, 13:751-758.
14. Dluzen D.E., Anderson L.I., Pilati C.F. Methamphetamine-gonadal steroid hormonal interactions: effects upon acute toxicity and striatal dopamine concentrations. Neurotoxicol. Teratol. 2002, 24:267-273.
15. Doudet D.J., Holden J.E. Sequential versus nonsequential measurement of density and affinity of dopamine D2 receptors with [11C]raclopride: effect of methamphetamine. J. Cereb. Blood Flow Metab. 2003, 23:1489-1494.
16. Eidelberg D., Moeller J.R., Dhawan V., Spetsieris P., Takikawa S., Ishikawa T., Chaly T., Robeson W., Margouleff D., Przedborski S. The metabolic topography of parkinsonism. J. Cereb. Blood Flow Metab. 1994, 14:783-801.
17. Forman S.D., Cohen J.D., Fitzgerald M., Eddy W.F., Mintun M.A., Noll D.C. Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): use of a cluster-size threshold. Magn. Reson. Med. 1995, 33:636-647.
18. Fornai F., Lenzi P., Gesi M., Ferrucci M., Lazzeri G., Capobianco L., de Blasi A., Battaglia G., Nicoletti F., Ruggieri S., Paparelli A. Similarities between methamphetamine toxicity and proteasome inhibition. Ann. N.Y. Acad. Sci. 2004, 1025:162-170.
19. Friston K.J., Holmes A.P., Worsley K.J., Poline J.P., Frith C.D., Frackowiak R.S.J. Statistical parametric maps in functional imaging: a general linear approach. Hum. Brain Mapp. 1995, 2:189-210.
20. Garcia de Yebenes J., Yebenes J., Mena M.A. Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease. Neurotox. Res. 2000, 2:115-137.
21. Gouzoulis-Mayfrank E., Schreckenberger M., Sabri O., Arning C., Thelen B., Spitzer M., Kovar K.A., Hermle L., Bull U., Sass H. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F]FDG. Neuropsychopharmacology 1999, 20:565-581.
22. Hwang J., Lyoo I.K., Kim S.J., Sung Y.H., Bae S., Cho S.N., Lee H.Y., Lee D.S., Renshaw P.F. Decreased cerebral blood flow of the right anterior cingulate cortex in long-term and short-term abstinent methamphetamine users. Drug Alcohol Depend. 2006, 82:177-181.
23. Iyo M., Namba H., Yanagisawa M., Hirai S., Yui N., Fukui S. Abnormal cerebral perfusion in chronic methamphetamine abusers: a study using 99MTc-HMPAO and SPECT. Prog. Neuropsychopharmacol. Biol. Psychiatry 1997, 21:789-796.
24. Johanson C.E., Frey K.A., Lundahl L.H., Keenan P., Lockhart N., Roll J., Galloway G.P., Koeppe R.A., Kilbourn M.R., Robbins T., Schuster C.R. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl.) 2006, 185:327-338.
25. Kao C.H., Wang S.J., Yeh S.H. Presentation of regional cerebral blood flow in amphetamine abusers by 99Tcm-HMPAO brain SPECT. Nucl. Med. Commun. 1994, 15:94-98.
26. Kim S.J., Lyoo I.K., Hwang J., Sung Y.H., Lee H.Y., Lee D.S., Jeong D.U., Renshaw P.F. Frontal glucose hypometabolism in abstinent methamphetamine users. Neuropsychopharmacology 2005, 30:1383-1391.
27. Kita T., Wagner G.C., Nakashima T. Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J. Pharmacol. Sci. 2003, 92:178-195.
28. Kraemer T., Maurer H.H. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther. Drug Monit. 2002, 24:277-289.
29. Kulsudjarit K. Drug problem in southeast and southwest Asia. Ann. N.Y. Acad. Sci. 2004, 1025:446-457.
30. London E.D., Simon S.L., Berman S.M., Mandelkern M.A., Lichtman A.M., Bramen J., Shinn A.K., Miotto K., Learn J., Dong Y., Matochik J.A., Kurian V., Newton T., Woods R., Rawson R., Ling W. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch. Gen. Psychiatry 2004, 61:73-84.
31. Mark K.A., Soghomonian J.J., Yamamoto B.K. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J. Neurosci. 2004, 24:11449-11456.
32. Marsh R., Zhu H., Schultz R.T., Quackenbush G., Royal J., Skudlarski P., Peterson B.S. A developmental fMRI study of self-regulatory control. Hum. Brain Mapp. 2006, 27:848-863.
33. McCann U.D., Wong D.F., Yokoi F., Villemagne V., Dannals R.F., Ricaurte G.A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J. Neurosci. 1998, 18:8417-8422.
34. Nash J.F., Yamamoto B.K. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res. 1992, 581:237-243.
35. Packard M.G., Knowlton B.J. Learning and memory functions of the Basal Ganglia. Annu. Rev. Neurosci. 2002, 25:563-593.
36. Pontieri F.E., Crane A.M., Seiden L.S., Kleven M.S., Porrino L.J. Metabolic mapping of the effects of intravenous methamphetamine administration in freely moving rats. Psychopharmacology (Berl.) 1990, 102:175-182.
37. Preston K.L., Wagner G.C., Schuster C.R., Seiden L.S. Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain. Brain Res. 1985, 338:243-248.
38. Ricaurte G.A., Schuster C.R., Seiden L.S. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res. 1980, 193:153-163.
39. Rocher C., Gardier A.M. Effects of repeated systemic administration of d-Fenfluramine on serotonin and glutamate release in rat ventral hippocampus: comparison with methamphetamine using in vivo microdialysis. Naunyn Schmiedebergs Arch. Pharmacol. 2001, 363:422-428.
40. Romero C.A., Bustamante D.A., Zapata-Torres G., Goiny M., Cassels B., Herrera-Marschitz M. Neurochemical and behavioural characterisation of alkoxyamphetamine derivatives in rats. Neurotox. Res. 2006, 10:11-22.
41. Substance Abuse and Mental Health Services Administration, 2002. Office of Applied Studies, National Survey on Drug use and Health. Rockville, MD.
42. Stephans S.E., Yamamoto B.K. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 1994, 17:203-209.
43. Verdejo-Garcia A., Bechara A., Recknor E.C., Perez-Garcia M. Executive dysfunction in substance dependent individuals during drug use and abstinence: an examination of the behavioral, cognitive and emotional correlates of addiction. J. Int. Neuropsychol. Soc. 2006, 12:405-415.
44. Villemagne V., Yuan J., Wong D.F., Dannals R.F., Hatzidimitriou G., Mathews W.B., Ravert H.T., Musachio J., McCann U.D., Ricaurte G.A. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J. Neurosci. 1998, 18:419-427.
45. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Wong C., Logan J. Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am. J. Psychiatry 2001, 158:383-389.
46. Vollm B.A., de Araujo I.E., Cowen P.J., Rolls E.T., Kringelbach M.L., Smith K.A., Jezzard P., Heal R.J., Matthews P.M. Methamphetamine activates reward circuitry in drug naive human subjects. Neuropsychopharmacology 2004, 29:1715-1722.
47. Wagner G.C., Ricaurte G.A., Johanson C.E., Schuster C.R., Seiden L.S. Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate. Neurology 1980, 30:547-550.
48. Wagner G.C., Tekirian T.L., Cheo C.T. Sexual differences in sensitivity to methamphetamine toxicity. J. Neural. Transm. Gen. Sect. 1993, 93:67-70.
49. Walsh S.L., Wagner G.C. Motor impairments after methamphetamine-induced neurotoxicity in the rat. J. Pharmacol. Exp. Ther. 1992, 263:617-626.
50. Wang G.J., Volkow N.D., Chang L., Miller E., Sedler M., Hitzemann R., Zhu W., Logan J., Ma Y., Fowler J.S. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am. J. Psychiatry 2004, 161:242-248.
51. Wilson J.M., Kalasinsky K.S., Levey A.I., Bergeron C., Reiber G., Anthony R.M., Schmunk G.A., Shannak K., Haycock J.W., Kish S.J. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat. Med. 1996, 2:699-703.
52. Woolverton W.L., Cervo L., Johanson C.E. Effects of repeated methamphetamine administration on methamphetamine self-administration in rhesus monkeys. Pharmacol. Biochem. Behav. 1984, 21:737-741.